Results 71 to 80 of about 1,426,440 (199)
Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case study
Revista Portuguesa de Cardiologia, 2015 A 51-year-old woman presented with a one-year history of progressive dyspnea, WHO functional class III-IV and exercise-related syncope. Transthoracic echocardiography and computed tomography pulmonary angiography were performed, leading to a diagnosis of
Carlos Ortiz-Bautista +4 more
doaj +1 more source
Pulmonary Hypertension in a Patient with Essential Thrombocythemia [PDF]
, 2002 A 67-year-old woman with essential thrombocythemia (ET) developed acute heart failure and marked pulmonary hypertension (PH). No clear cause for the PH could be initially found. We suspected that thrombocytosis might cause PH.
Miyahara, Yoshiyuki +6 more
core
The Pulmonary Hypertension Association Registry: Rationale, Design, and Role in Quality Improvement
, 2018 The Pulmonary Hypertension Association (PHA) Scientific Leadership Council (SLC) prioritized the development of the PH Care Centers (PHCC) initiative in part to identify centers that adhere to expert consensus diagnostic and treatment guidelines in both ...
Michael P. Gray, Steven M. Kawut
core +1 more source
Pulmonary CirculationThe aim of this single‐centre retrospective observational study was to evaluate the safety, tolerability, and efficacy of an in‐class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary ...
Cara Morgan +7 more
doaj +1 more source
LifeGroup 1 of PAH patients encompasses patients with a diverse underlying etiological condition, having histological modifications that can affect gas exchange across the alveolar-capillary membrane, as reflected by decreased DLCO.
Effrosyni Dima +12 more
doaj +1 more source
Scientific ReportsTargeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic ...
Benchenouf Feriel +16 more
doaj +1 more source
PULMONARY ARTERIAL HYPERTENSION
Annals of Medicine, 2006 Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right ventricular failure. Vasoconstriction, vascular proliferation, remodeling of the pulmonary vessels, and thrombosis are all contributing factors to the increased ...
Azad, Raiesdana, Joseph, Loscalzo
openaire +2 more sources
DDAH1 regulates apoptosis and angiogenesis in human fetal pulmonary microvascular endothelial cells
Physiological Reports, 2019 Nitric Oxide (NO) is an endogenous pulmonary vasodilator produced by endothelial NO synthase (eNOS). Asymmetric dimethyl L‐arginine (ADMA) is an endogenous inhibitor of eNOS activity.
Jennifer K. Trittmann +3 more
doaj +1 more source
Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension
Journal of Cardiovascular Development and DiseaseBackground: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear.
Steven Hopkins +8 more
doaj +1 more source
Low-grade albuminuria in pulmonary arterial hypertension
, 2019 Low-grade albuminuria, determined by the urinary albumin to creatinine ratio, has been linked to systemic vascular dysfunction and is associated with cardiovascular mortality.
Fessel, Joshua P. +6 more
core +1 more source